Core Scientific, Inc./tx CORZ

Core Scientific, Inc. (tx) has just filed its latest 10-Q for the quarter ended 31 March 2026, and the numbers look like they were run through a crypto-mining blender set to “liquidity crisis.” Revenue clocked in at $115.2 million while the net loss attributable to parent ballooned to $347.2 million, turning a $310.4 million operating loss into a headline that reads like a typo. On the bright side-if you squint-the company managed to generate $249.9 million in operating cash, enough to keep the servers humming and the regulators quiet for another quarter.

What Core Scientific actually does is rent high-density cages to customers who need to park machines that, in theory, mine digital money. The company breaks its business into colocation services and, presumably, everything else it can bolt to a data-centre rack. Revenues for colocation are recognised within 30 months of licence order commencement, a rule that quietly assumes someone will sign a lease, someone will build something, and someone will actually start paying before the 30-month fuse expires. As of March 31 2026 the company’s leased property, plant and equipment sat on the books at $3.07 billion in assets versus $4.38 billion in liabilities, leaving shareholders staring down a $1.31 billion deficit in equity. Cash and equivalents were a rare bright spot at $1.01 billion, a sum large enough to fund daily operations and small enough to prompt questions about runway.

The latest 10-Q shows revenue of $115.2 million, a net loss of $347.2 million, operating loss of $310.4 million, total assets of $3.07 billion, total liabilities of $4.38 billion, and shareholders’ equity of negative $1.31 billion for the quarter ended 31 March 2026. Operating cash flow was $249.9 million while capex gobbled $389.2 million, and diluted EPS came in at negative $1.06 on 322.9 million diluted shares. R&D expense for the year ended 31 December 2024 was $11.8 million, a figure that feels almost quaint given the scale of the losses elsewhere in the filing.

Recent insider activity is a sideshow that refuses to leave the stage. Form 4 filings on 17 June, 10 June, 3 June, and two separate entries on 28 May 2026 all carry the same “CORZ 4” label, as if the ticker itself were a serial-number stamped on every disclosure. The filings list routine share transactions but offer no disclosure about what those transactions signify beyond the legal minimum. The SEC EDGAR index for Core Scientific runs to dozens of submissions, yet none of the current disclosures explain how the revenue-recognition rule translates into cash that shareholders can touch. The company’s own filings admit the colocation segment recognises revenue within 30 months of licence order commencement, a timeline that only underscores how much of the business remains prospective rather than realised.

Anyone hunting for a chart will find the company’s share price orbiting a venue that isn’t Core Scientific’s primary exchange, a reminder that the stock trades where liquidity gathers rather than where the business operates. Without a formal chart route supplied, the best we can say is that the equity is listed on a regional exchange and its price action is shaped by forces outside the company’s filings. The SEC companyfacts feed and submissions JSON confirm the filing trail but add no colour about market microstructure or liquidity depth.

The tension in the file is simple: the company’s cash position is healthy on paper, yet its equity hole yawns $1.31 billion wide. The colocation revenue rule is a legal fiction until the cages fill and the invoices clear. Insider filings tick along like metronomes while the balance sheet ticks in the opposite direction. Until revenues convert to cash that can service debt or fund growth, the story is less “growth company” and more “liquidity management exercise.” What would change the file next is a quarter in which colocation revenues exceed the 30-month recognition threshold in substance as well as form, coupled with evidence that the $1.01 billion cash pile is being deployed to shrink liabilities rather than merely tide over the next filing cycle.